Wockhardt Ltd. has created history in the Indian pharmaceutical industry after the US Food and Drug Administration (US FDA) formally accepted its New Drug Application (NDA) for Zaynich, the company’s breakthrough antibiotic candidate. This development sent the company’s shares soaring over 12% to ₹1,386.90, marking one of the sharpest intraday moves in recent months.
According to the company, the NDA for Zaynich was submitted on September 30, and its acceptance represents a historic first for the Indian pharma sector. This is the first time ever that the US FDA has accepted an NDA for a New Chemical Entity (NCE) developed by an Indian company — a milestone that has generated significant attention across the market and the industry.
Zaynich is Wockhardt’s novel, first-in-class antibiotic, developed specifically to combat resistant bacterial infections, a medical challenge that has seen limited global innovation.
The company highlighted that Zaynich represents years of scientific research aimed at addressing antimicrobial resistance — a growing global threat where many existing medicines are becoming ineffective.
Wockhardt emphasised that the acceptance of the NDA demonstrates the scientific strength and innovation capability behind the drug’s development. It also reflects the company’s long-term commitment to advancing novel antibacterial solutions at a time when global pipelines for new antibiotics remain sparse.
Wockhardt stated that this regulatory acceptance is not just significant for the company but marks a major breakthrough for India’s pharmaceutical industry as a whole.
For decades, India has been known globally as the “pharmacy of the world” — largely for its leadership in generic drugs. However, innovation in new drug discovery, especially in the area of New Chemical Entities, has been a long-standing goal for the country’s pharma sector.
The acceptance of Zaynich’s NDA by the US FDA is seen as a step forward in elevating India’s presence in the global innovation landscape.
According to the company, the regulatory progress affirms that Indian firms are capable of developing high-quality, first-in-class medicines that meet global standards for safety, efficacy, and innovation.
Also Read: India’s Manufacturing Slows to 9-Month Low at 56.6 in November, Still Strongly in Expansion Mode
The company clarified that the US FDA’s NDA acceptance does not represent final approval but is a major advancement in the overall approval process.
Wockhardt said it will continue to work closely with the US regulator as Zaynich moves into the next stage of review. The company reaffirmed its commitment to bringing the antibiotic solution to global markets at a time when treatment options for resistant infections are limited.
The announcement signals confidence in the drug’s clinical dossier and paves the way for further regulatory milestones in the coming months.
Following the announcement, Wockhardt shares jumped more than 12%, touching ₹1,386.90 during the session.
The stock’s strong move reflects the market’s positive sentiment toward the company’s breakthrough achievement and the potential value of Zaynich in the future.
However, despite today’s sharp gain, the company noted that its stock remains down 5% so far in 2025.
Market analysts believe that regulatory progress for Zaynich is a key development that could influence investor sentiment and long-term interest in the stock.
The news of Wockhardt’s milestone comes amid several significant updates across India’s health and medical landscape:
Fischer Medical partnered with Indonesia’s PT Pariko to support tuberculosis eradication efforts.
The Indian government has directed smartphone makers to preload a state-owned cyber safety app.
India has proposed new cess structures on pan masala and increased excise duties on tobacco products.
Mumbai witnessed a smog-filled morning, with severe pollution prompting the enforcement of GRAP-4 restrictions.
While these updates are not directly linked to Wockhardt, they reflect a broader environment where healthcare innovation, public health concerns, and regulatory developments remain in strong focus.
Wockhardt stated that Zaynich remains one of its most significant research achievements and reiterated its dedication to pushing the drug through the US FDA’s approval pipeline.
The company emphasised that the NDA acceptance serves as validation of its long-standing investment in scientific innovation and its efforts to address critical global health challenges.
Note to Readers
The article includes information provided by the company and market data available at the time of reporting.
A reminder that investment views and tips expressed on platforms like CNBCTV18.com belong solely to experts and are not endorsed by the website. Readers are advised to consult certified professionals before making investment decisions.
Click here to explore
Gift Nifty
FII DII Data
IPO
Petronet LNG’s stock saw a sharp upmove on December 4, rising more than 4 percent…
The domestic equity market staged a sharp recovery on Friday as the Sensex surged over…
India’s financial markets have entered a phase defined by conflicting forces, as the Reserve Bank…
The momentum in public sector bank (PSU bank) stocks took a noticeable pause this week…
The IPO market witnessed strong action on Friday as Meesho, Aequs, and Vidya Wires entered…
ITC Hotels witnessed one of its biggest trading sessions in recent months as a massive…
This website uses cookies.